NCT01429064View on ClinicalTrials.gov

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Prostate Cancer
Interventions
DRUG

ODM-201

ODM-201 administered orally daily

Trial Locations (17)

29572

Carolina Urologic Research Center, Myrtle Beach

44195

Cleveland Clinic, Cleveland

80211

The Urology Center of Colorado, Wheat Ridge

06360

Eastern CT Hematology and Oncology Associates, Norwich

Unknown

Klinika onkologie a radioterapie LFUK a FN, Hradec Králové

East-Tallinn Central Hospital, Tallinn

Helsinki University Central Hospital, Helsinki

Kuopio University Hospital, Kuopio

Oulu University Hospital, Oulu

Tampere University Hospital, Tampere

Turku University Hospital, Turku

Saint Louis Hospital, Paris

Institut Gustave Roussy, Villejuif

Queen Elizabeth Hospital, Birmingham

Velindre Cancer Centre, Cardiff

Christie Hospital, Manchester

Churchill Hospital, Oxford

All Listed Sponsors
lead

Orion Corporation, Orion Pharma

INDUSTRY

NCT01429064 - Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001 | Biotech Hunter | Biotech Hunter